Review



goat anti guinea pig c3 antibody  (Valiant Co Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Valiant Co Ltd goat anti guinea pig c3 antibody
    Goat Anti Guinea Pig C3 Antibody, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/Goat+Anti-Guinea+Pig+Complement+C3/pm42801862-227-5-10
    Average 96 stars, based on 52 article reviews
    goat anti guinea pig c3 antibody - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and in vitro antibody-dependent enhancement
    Article Snippet: .. To inactivate complement, the serum was diluted 1:500 in RPMI medium and incubated at 56°C for 30 min. For the complement rescue experiment, guinea pig complement (MP Biomedicals, Santa Ana, CA, USA; catalog #086428-CF) was added at a 1:50 dilution following heat treatment. ..

    Article Title: Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection
    Article Snippet: .. For assessment of opsonophagocytosis in the presence of complement, an identical procedure was followed with the addition of 30% guinea pig Complement (MP Biomedicals, Fisher Scientific, #ICN642831) and incubation at 37°C for 30 min. Heat-inactivated guinea pig complement was used as a negative control. .. Macrophages were incubated at an MOI of 10:1 in the presence of 30 μg/mL WVDC-2109, IgG2b Isotype Control (Bio X Cell #BE0086), or MEM +1% BSA for 2 h using end-over-end rotation at 37°C.

    Article Title: COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and in vitro antibody-dependent enhancement
    Article Snippet: The cells were washed again twice and resuspended in 800 μL of FACS buffer and subjected to flow cytometry (Thermo Attune NxT cell analysis). .. For the ADCD assay, the antibody complexes were incubated in 1/50 guinea pig complement (MP Biomedicals, Santa Ana, CA, USA; cat# 086428-CF) in RPMI 1640 medium for 15 min, followed by two washes with 15 mM EDTA in PBS. .. The beads were then incubated with an anti-goat C3 antibody (MP Biomedicals; cat# 0855367) for 15 min, followed by two washes, and incubation with an anti-goat fluorescent antibody (donkey anti-goat IgG H&L, AF647 Abcam cat# ab150135) for 15 min. Next, the beads were resuspended in 1 mL FACS buffer for flow cytometry.

    Negative Control:

    Article Title: Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection
    Article Snippet: .. For assessment of opsonophagocytosis in the presence of complement, an identical procedure was followed with the addition of 30% guinea pig Complement (MP Biomedicals, Fisher Scientific, #ICN642831) and incubation at 37°C for 30 min. Heat-inactivated guinea pig complement was used as a negative control. .. Macrophages were incubated at an MOI of 10:1 in the presence of 30 μg/mL WVDC-2109, IgG2b Isotype Control (Bio X Cell #BE0086), or MEM +1% BSA for 2 h using end-over-end rotation at 37°C.

    other:

    Article Title: COVID-19 Vaccination Induces Cross-Reactive Dengue Antibodies with Altered Isotype Profiles and In Vitro ADE
    Article Snippet: For the complement rescue experiment, guinea pig complement (MP Biomedicals, Santa Ana, CA, USA; catalog #086428-CF) was added at a 1:50 dilution following heat treatment.

    Plaque Reduction Neutralization Test:

    Article Title: The structural basis of protective and nonprotective human monoclonal antibodies targeting the parainfluenza virus type 3 hemagglutinin-neuraminidase.
    Article Snippet: Samples were read on the Novocyte Quanteon. .. A PRNT was performed as described above with the addition of a guinea pig complement (MPBiomedicals, Cat #8642836). ..



    Similar Products

    guinea pig complement rockland cat  (Rockland Immunochemicals)
    93
    Rockland Immunochemicals guinea pig complement rockland cat
    Guinea Pig Complement Rockland Cat, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/Guinea+Pig+Complement/pm42805179-302-59-62
    Average 93 stars, based on 1 article reviews
    guinea pig complement rockland cat - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    goat anti guinea pig c3 antibody  (Valiant Co Ltd)
    96
    Valiant Co Ltd goat anti guinea pig c3 antibody
    Goat Anti Guinea Pig C3 Antibody, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/Goat+Anti-Guinea+Pig+Complement+C3/pm42801862-227-5-10
    Average 96 stars, based on 1 article reviews
    goat anti guinea pig c3 antibody - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    guinea pig complement c3  (Valiant Co Ltd)
    96
    Valiant Co Ltd guinea pig complement c3
    Guinea Pig Complement C3, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/Guinea+Pig+Complement/pm42785303-577-11-15
    Average 96 stars, based on 1 article reviews
    guinea pig complement c3 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    anti guinea pig c3 fitc  (Valiant Co Ltd)
    96
    Valiant Co Ltd anti guinea pig c3 fitc
    Anti Guinea Pig C3 Fitc, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/FITC+IgG+Goat+Anti-Guinea+Pig+Complement+C3/pm42035419-221-10-14
    Average 96 stars, based on 1 article reviews
    anti guinea pig c3 fitc - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    fitc igg goat anti-guinea pig complement c3  (Valiant Co Ltd)
    96
    Valiant Co Ltd fitc igg goat anti-guinea pig complement c3
    Fitc Igg Goat Anti Guinea Pig Complement C3, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/FITC+IgG+Goat+Anti-Guinea+Pig+Complement+C3/custom%400855385%4042035419
    Average 96 stars, based on 1 article reviews
    fitc igg goat anti-guinea pig complement c3 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    guinea pig complement  (Cedarlane)
    96
    Cedarlane guinea pig complement
    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent <t>complement</t> deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).
    Guinea Pig Complement, supplied by Cedarlane, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/Low-Tox%C2%AE+Guinea+Pig+Complement%2C+Lyophilized/pmc12999348-30-0-4
    Average 96 stars, based on 1 article reviews
    guinea pig complement - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    goat anti guinea pig c3 fluorescein antibody  (Valiant Co Ltd)
    96
    Valiant Co Ltd goat anti guinea pig c3 fluorescein antibody
    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent <t>complement</t> deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).
    Goat Anti Guinea Pig C3 Fluorescein Antibody, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/FITC+IgG+Goat+Anti-Guinea+Pig+Complement+C3/pmc12999348-13-0-7
    Average 96 stars, based on 1 article reviews
    goat anti guinea pig c3 fluorescein antibody - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    fluorescein conjugated goat anti guinea pig c3 antibody  (Valiant Co Ltd)
    96
    Valiant Co Ltd fluorescein conjugated goat anti guinea pig c3 antibody
    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent <t>complement</t> deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).
    Fluorescein Conjugated Goat Anti Guinea Pig C3 Antibody, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/FITC+IgG+Goat+Anti-Guinea+Pig+Complement+C3/pmc12999348-269-7-13
    Average 96 stars, based on 1 article reviews
    fluorescein conjugated goat anti guinea pig c3 antibody - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    cl4051  (Cedarlane)
    96
    Cedarlane cl4051
    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent <t>complement</t> deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).
    Cl4051, supplied by Cedarlane, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/guinea+pig+complement/Low-Tox%C2%AE+Guinea+Pig+Complement%2C+Lyophilized/pmc12999348-30-7-4
    Average 96 stars, based on 1 article reviews
    cl4051 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Article Snippet: Guinea pig complement , Cedarlane , Cat# CL4051.

    Techniques: Infection, Comparison, Transformation Assay, Vaccines, Whisker Assay